EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits

Joyce Mei Xin Yip iD, Grace Shu Hui Chiang iD, Ian Chong Jin Lee, Rachel Lehming-Teo, Kexin Dai iD, Lokeysh Dongol, Laureen Yi-Ting Wang iD, Denise Teo iD, Geok Teng Seah iD, Norbert Lehming iD

International Journal of Molecular Sciences · 03.01.2025 · 26 (1) · 364

DOI: 10.3390/ijms26010364 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.01.2025. Verfasst von Joyce Mei Xin Yip und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. Hauptthemen laut MEDLINE: Drug Repositioning, Hypoglycemic Agents, Mitochondria, COVID-19 Drug Treatment. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 430 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review describes our current understanding of the role of the mitochondria in the repurposing of the anti-diabetes drugs metformin, gliclazide, GLP-1 receptor agonists, and SGLT2 inhibitors for additional clinical benefits regarding unhealthy aging, long COVID, mental neurogenerative disorders, and obesity. Metformin, the most prominent of these diabetes drugs, has been called the “Drug of Miracles and Wonders,” as clinical trials have found it to be beneficial for human patients suffering from these maladies. To promote viral replication in all infected human cells, SARS-CoV-2 stimulates the infected liver cells to produce glucose and to export it into the blood stream, which can cause diabetes in long COVID patients, and metformin, which reduces the levels of glucose in the blood, was shown to cut the incidence rate of long COVID in half for all patients recovering from SARS-CoV-2. Metformin leads to the phosphorylation of the AMP-activated protein kinase AMPK, which accelerates the import of glucose into cells via the glucose transporter GLUT4 and switches the cells to the starvation mode, counteracting the virus. Diabetes drugs also stimulate the unfolded protein response and thus mitophagy, which is beneficial for healthy aging and mental health. Diabetes drugs were also found to mimic exercise and help to reduce body weight.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningHypoglycemic AgentsMitochondriaCOVID-19 Drug TreatmentDiabetes MellitusHumansCOVID-19MetforminSARS-CoV-2Off-Label Use

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT2 inhibitorsgliclazidelong COVIDmental neurogenerative disordersmetforminobesityunhealthy aging

Substanzen

Hypoglycemic AgentsMetformin

Autor:innen und Institutionen

  • Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
  • Well Programme, Alexandra Hospital, National University Health System, Singapore 159964, Singapore.
  • NUS High School of Mathematics and Science, Singapore 129957, Singapore.
  • Department of Cardiology, National University Heart Centre, National University Health System, Singapore 119074, Singapore.
  • Division of Cardiology, Department of Medicine, Alexandra Hospital, National University Health System, Singapore 159964, Singapore.
  • Chi Longevity, Camden Medical Centre #10-04, 1 Orchard Blvd, Singapore 248649, Singapore.

ORCID-Profile: Joyce Mei Xin Yip, Grace Shu Hui Chiang, Kexin Dai, Laureen Yi-Ting Wang, Denise Teo, Geok Teng Seah, Norbert Lehming

Förderung

  • Ministry of Education

Zitieren

APA

Yip, J. M. X., Chiang, G. S. H., Lee, I. C. J., Lehming-Teo, R., Dai, K., Dongol, L., Wang, L. Y., Teo, D., Seah, G. T., & Lehming, N. (2025). Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits. International Journal of Molecular Sciences, 26(1), 364. https://doi.org/10.3390/ijms26010364

Vancouver

Yip JMX, Chiang GSH, Lee ICJ, Lehming-Teo R, Dai K, Dongol L, et al. Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits. International Journal of Molecular Sciences. 2025;26(1):364. doi:10.3390/ijms26010364

BibTeX
@article{Yip2025,
  author = {Yip, Joyce Mei Xin and Chiang, Grace Shu Hui and Lee, Ian Chong Jin and Lehming-Teo, Rachel and Dai, Kexin and Dongol, Lokeysh and Wang, Laureen Yi-Ting and Teo, Denise and Seah, Geok Teng and Lehming, Norbert},
  title = {Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {1},
  pages = {364},
  doi = {10.3390/ijms26010364}
}
Kostenlos starten →